<?xml version="1.0" encoding="UTF-8"?><rss xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:content="http://purl.org/rss/1.0/modules/content/" xmlns:atom="http://www.w3.org/2005/Atom" version="2.0" xmlns:cc="http://cyber.law.harvard.edu/rss/creativeCommonsRssModule.html">
    <channel>
        <title><![CDATA[MDplus - Medium]]></title>
        <description><![CDATA[MD+ is a community of medical students and young physicians across the country pursuing interdisciplinary career paths that combine clinical medicine with healthcare innovation. - Medium]]></description>
        <link>https://medium.com/mdplus?source=rss----ab0ea1775307---4</link>
        <image>
            <url>https://cdn-images-1.medium.com/proxy/1*TGH72Nnw24QL3iV9IOm4VA.png</url>
            <title>MDplus - Medium</title>
            <link>https://medium.com/mdplus?source=rss----ab0ea1775307---4</link>
        </image>
        <generator>Medium</generator>
        <lastBuildDate>Thu, 19 Nov 2026 10:52:41 GMT</lastBuildDate>
        <atom:link href="https://medium.com/feed/mdplus" rel="self" type="application/rss+xml"/>
        <webMaster><![CDATA[yourfriends@medium.com]]></webMaster>
        <atom:link href="http://medium.superfeedr.com/" rel="hub"/>
        <item>
            <title><![CDATA[Alumni Spotlight: Dr. Yasmine Abbey]]></title>
            <link>https://medium.com/mdplus/alumni-spotlight-dr-yasmine-abbey-f4af88b8494e?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/f4af88b8494e</guid>
            <dc:creator><![CDATA[Darshan Kalola]]></dc:creator>
            <pubDate>Mon, 08 Dec 2025 15:32:21 GMT</pubDate>
            <atom:updated>2025-12-08T15:32:20.601Z</atom:updated>
            <content:encoded><![CDATA[<p>If you’re a medical student curious about non-clinical career paths but don’t want to step away from patients entirely, Yasmine Abbey’s story is a great reminder that the boundary between a career in clinical medicine and a career in technology isn’t as strict as it may seem.</p><p>Yasmine was born and raised in Benin before moving to Chicago. Her initial interest in medicine developed in high school. After doing research in multiple wet labs, she realized she didn’t want her work to live only at the bench. She wanted to be closer to impact, such as the work that affected patients directly and immediately.</p><p>She attended Vassar College in Poughkeepsie, New York, where she studied biochemistry with a creative writing minor. Even then, her interests stretched across disciplines: she also spent about a year taking computer science courses.</p><p>After graduating from Vassar, she completed a master’s program at Johns Hopkins, and then started medical school at UCLA. Medical school brought the usual intensity and challenges: the firehose of information, the steep learning curve, the constant recalibration. But Yasmine credits the support system of her friends and colleagues for making the tough transition a lot more manageable.</p><p>After her third year, she was named a UCLA Deans Leaders in Health in Science Fellow, which led to a research year, during which she worked on two impactful projects: assessing racial bias and the use of chemical restraints in the trauma setting, and evaluating the efficacy of anti-racist learning groups.</p><p>When it came time to choose a specialty, internal medicine felt like the right choice. Yasmine was drawn to its breadth and variety. Training in internal medicine would allow her to use everything she learned in medical school and allow her to remain a generalist.</p><p>As a third year Internal Medicine Resident at Cedar Sinai, Yasmine began building a suite of tools hosted on a website called <a href="https://notomed.dev/">notomed.dev</a>. The project started when she noticed friction points in her own clinical workflow, such as repetitive processes, calculations that interrupted flow, and documentation burdens that slowed thinking. Instead of accepting these frustrations as “just how it is,” she began automating them for herself.</p><p>The first tool was a hyponatremia calculator. The set expanded quickly to 6 tools (and growing), which include an opioid regimen builder, an AI-powered pre-op risk stratifier and an AI powered summarizer that features a comprehensive PHI scrubber.</p><p>She built these tools using a baseline understanding of computer programming from college and with the assistance of large LLM models such ChatGPT and Google Gemini. She uses these tools regularly and many of her friends and colleagues now use them too.</p><p>Her advice for anyone who wants to build apps without formal computer science training is to start simple and learn the basics. Even a few YouTube videos on logic, structure, and syntax can allow one to make the most of “vibe coding” with the modern AI tools.</p><p>Yasmine expects to work as a hospitalist after graduation, but she doesn’t see that as a fork in the road away from tech. She imagines a career split roughly 50/50 — clinical work alongside non-clinical work. In the near term, that might mean joining a company, learning from experienced builders, and getting closer to product development. Longer term, she can easily imagine starting something of her own.</p><p>In a world where many trainees feel forced to pick one identity — clinician or technologist, patient-facing or system-building — Yasmine’s path offers a third option: be both, and let each role improve the other.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=f4af88b8494e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/alumni-spotlight-dr-yasmine-abbey-f4af88b8494e">Alumni Spotlight: Dr. Yasmine Abbey</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[MD+ Alumni Spotlight: Lathan Liou]]></title>
            <link>https://medium.com/mdplus/md-alumni-spotlight-lathan-liou-e399a9779520?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/e399a9779520</guid>
            <dc:creator><![CDATA[Darshan Kalola]]></dc:creator>
            <pubDate>Wed, 05 Nov 2025 22:51:45 GMT</pubDate>
            <atom:updated>2025-11-05T22:51:43.836Z</atom:updated>
            <content:encoded><![CDATA[<p>From the start of his undergraduate years at Pomona College, Lathan’s journey has been marked by curiosity and an inclination to pursue the unconventional path.</p><p>As a Pomona undergrad, he served as the Executive Director of Refresh Bolivia, a nonprofit dedicated to improving public health infrastructure in Bolivian communities. The organization remains active today. It has raised over $100,000 and continues to run service trips and health initiatives.</p><p>In his second year of undergrad, Lathan was accepted into the prestigious FlexMed program at Mount Sinai’s Icahn School of Medicine — a unique early assurance program that guaranteed acceptance to medical school with no MCAT requirements.</p><p>That academic freedom led Lathan to study mathematics, where he found a passion for applied biostatistics. By his senior year, his growing interest in public health pushed him to look beyond the United States. He applied for several international scholarships and was ultimately accepted to the University of Cambridge for an MPhil in Epidemiology.</p><p>At Cambridge, Lathan found what he calls his “Hogwarts moment.” Immersed in the university’s historic house culture and surrounded by brilliant peers, he discovered a deep sense of intellectual curiosity about genomics. His advisor — a leading physician-scientist in breast cancer and cancer epidemiology — became an inspiring mentor and later his thesis advisor. The experience was so transformative that Lathan even considered staying to pursue a PhD.</p><p>As his MPhil came to a close, Lathan found himself at a crossroads: continue at Cambridge for a PhD under the same advisor, or take a job offer from Merck, one of the world’s top pharmaceutical companies. In the end, he chose industry. “I felt I would learn more real-world skills there,” he recalls. “It was a new experience, something different.”</p><p>Lathan joined Merck’s data science team in Boston, gaining hands-on experience in large-scale biomedical data analysis. Meanwhile, he deferred his Mount Sinai admission — first for the MPhil, then again for Merck.</p><p>When he finally began his medical studies at Mount Sinai, Lathan’s interests naturally gravitated toward the intersection of medicine, data, and technology. Around that time, he met Sherman, who was starting an initiative called MD+ (it was known as MD++ back then). Lathan soon became deeply involved — helping to build its data infrastructure and eventually leading the organization himself. During his tenure, one of his proudest accomplishments was launching the MD+ Datathon, an initiative that continues to thrive today.</p><p>Now in his fourth year at Mount Sinai, Lathan is applying to internal medicine residency while continuing his research in biostatistics, genomics, and computational biology. His work sits at the frontier of medicine and data science, and he envisions a career that bridges both.</p><p>From Pomona to Cambridge to Mount Sinai, Lathan’s path hasn’t followed the straight line most expect — but that’s precisely what makes it extraordinary. His journey is a testament to how curiosity, flexibility, and a willingness to explore can shape not just a career, but a calling.</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=e399a9779520" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/md-alumni-spotlight-lathan-liou-e399a9779520">MD+ Alumni Spotlight: Lathan Liou</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Alumni Spotlight: Dr. Pranav Sanghvi, MD, MBA]]></title>
            <link>https://medium.com/mdplus/alumni-spotlight-dr-pranav-sanghvi-md-mba-1b5202ef1dee?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/1b5202ef1dee</guid>
            <dc:creator><![CDATA[Darshan Kalola]]></dc:creator>
            <pubDate>Sat, 23 Aug 2025 01:20:59 GMT</pubDate>
            <atom:updated>2025-08-23T01:20:59.276Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Pranav Sanghvi is a physician innovator, consultant, and entrepreneur operating at the intersection of healthcare, life sciences, and AI. He studied biomedical engineering at East Carolina University, where he earned grants for 3D printing applications in surgical planning and medical education and gained early experience in machine learning, business development, and project management.</em></p><p><em>During his MD/MBA at UNC, he co-founded the Dermatology Image Library to improve diversity in medical education, led strategy projects for major health systems and life science companies, worked as a Summer Consultant at EY Parthenon, and supported digital health and AI startup investments at Excelerate Health Ventures.</em></p><p><em>Currently, he is a Co-Founder of Carbonix AI, where he’s developing generative AI infrastructure to streamline clinical trial workflows. He also advises biopharma and MedTech companies on strategy and product innovation, and co-hosts The Medical Innovation Podcast, where he explores the future of healthcare innovation with leaders across the industry.</em></p><p><strong>How did you first hear about the MD+ community?</strong></p><p>I first heard about MD+ from my friend Arvind early in my third year of medical school. He joined when he started med school and spoke highly of the community, so I decided to join shortly after. Initially, I wasn’t too active. I would browse the Slack channels and apply to interesting opportunities, but I quickly realized that it was an incredible way to meet like-minded people pursuing diverse paths in healthcare. Since I decided relatively early in med school that I wasn’t interested in pursuing a traditional clinical career, MD+ became invaluable for meeting others exploring non-traditional career trajectories. The community provided both inspiration and practical guidance that I couldn’t find elsewhere in medical school. Last year, I joined the executive team as a Director of Consulting, where I planned networking and informational events, developed career resources, and mentored medical students and residents with similar interests. It’s been extremely rewarding to give back to a community that played such an important role in shaping my own non-traditional path.</p><p><strong>What led you to pursue medical school in the first place? Why did you not pursue residency after graduating?</strong></p><p>Medical school was always the plan for me. I’ve been interested in healthcare for as long as I can remember and always wanted to do something where I could help patients live healthy and fulfilling lives. I volunteered in hospitals in high school, studied biomedical engineering, conducted medical research, and even became an EMT, all with the intention of becoming a physician. Though I had interests in business, software, real estate, and beyond, I initially considered them side projects. However, once I started medical school, I realized I was consistently more energized by the projects and initiatives I was working on outside of my clinical responsibilities. Whether it was working with startups or exploring healthcare innovation projects, these experiences felt more aligned with how I wanted to make an impact. I figured, why not pursue those aspirations full-time and leverage the MD degree in a different way to still serve patients and the healthcare system?</p><p><strong>You spent a summer at EY-Parthenon. What did that look like and how did your clinical background inform your day to day work?</strong></p><p>I did a five-year MD/MBA program: three years of med school, one year of MBA, and a hybrid year. The EY-Parthenon internship fell between my fourth and fifth year. I spent the summer in Boston, where much of their healthcare and life sciences practices are based. I worked on several different projects, including strategy development for a major children’s health system and growth strategy for a specialty digital pharmacy. It was fascinating to see the healthcare industry from a new lens and collaborate in truly multidisciplinary teams. My clinical background proved invaluable as it provided context and real-world experience that directly informed our project recommendations. There were countless instances when my managers or partner would specifically seek out my clinical perspective to validate assumptions or refine our strategic approach.</p><p><strong>What advice do you have for students considering an MD/MBA? What aspects of the MBA were the most valuable to you?</strong></p><p>I would encourage any medical student interested in exploring healthcare from a new perspective or pursuing non-traditional career paths to consider an MD/MBA. Taking a year or two to step back from clinical medicine can open doors to opportunities you may never have considered otherwise. Through my MBA program, I was able to consult for major MedTech companies, secure a venture capital fellowship, and work on so many interesting projects both within and outside of healthcare. While it’s possible to land similar opportunities in medical school, having dedicated time to fully immerse yourself in building your network and exploring new opportunities makes a significant difference. Beyond new experiences, it was also an invaluable way to meet highly motivated people with diverse backgrounds and skill sets who challenged me to think differently about problems in healthcare and beyond.</p><p><strong>You and Arvind co-host The Medical Innovation Podcast. How did that start and what has the experience been like so far?</strong></p><p>Arvind and I have been friends since undergrad and over time we bonded over our shared passion for innovation at the intersection of healthcare and technology. We were constantly exchanging interesting articles, brainstorming new project ideas, and discussing fascinating conversations we’d had with innovators in the space. Eventually we realized we were already having these incredible conversations, so why not turn it into a podcast? We launched with a couple of introductory episodes where we shared our perspectives on AI in healthcare, then began leveraging both our existing network and cold outreach to connect with guests who inspired us. The response has been incredible — we’ve hosted leaders from companies like OpenEvidence, Microsoft, Glass Health, Vista AI, and many other organizations at the cutting edge of healthtech innovation. We continue to surprise ourselves by the caliber of guests we are able to attract and their willingness to share their stories with our audience. Beyond just creating content, the podcast has become a powerful relationship-building tool, opening doors to connections and conversations we might never have had otherwise. It’s been incredibly rewarding to bridge the gap between these innovators and our audience who are equally passionate about the future of healthcare.</p><p><em>Interview conducted by Darshan Kalola</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=1b5202ef1dee" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/alumni-spotlight-dr-pranav-sanghvi-md-mba-1b5202ef1dee">Alumni Spotlight: Dr. Pranav Sanghvi, MD, MBA</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Recap of 2023 MD+ Datathon]]></title>
            <link>https://medium.com/mdplus/recap-of-2023-md-datathon-17b677af3c33?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/17b677af3c33</guid>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[medical]]></category>
            <category><![CDATA[value-based-care]]></category>
            <category><![CDATA[healthcare-innovations]]></category>
            <category><![CDATA[medical-school]]></category>
            <dc:creator><![CDATA[Lathan Liou]]></dc:creator>
            <pubDate>Tue, 28 Nov 2023 15:09:30 GMT</pubDate>
            <atom:updated>2023-11-28T15:09:30.207Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*8rWletqu0fFMhyzk" /><figcaption>Photo by <a href="https://unsplash.com/@swimstaralex?utm_source=medium&amp;utm_medium=referral">Alexander Sinn</a> on <a href="https://unsplash.com/?utm_source=medium&amp;utm_medium=referral">Unsplash</a></figcaption></figure><p>Our successful <a href="https://medium.com/mdplus/inaugural-md-datathon-2022-4947b28b2181">inaugural datathon</a> last year culminated in publications and students from multi-disciplinary backgrounds teaming up to identify problems and solutions within in-patient care using the real-world National Inpatient Sample dataset! We initially conceptualized the MD+ Datathon as an opportunity for medical students to learn quantitative skills, think critically about how to translate data insights into business or policy actions and connect with other data-driven people. At MD+, we also know that aspiring physician-innovators who want to work on impactful ideas gravitate toward us. So, we agreed that creating an event around optimizing value-based care was timely and increasingly important. We are so pleased to organize a sequel datathon focused on value-based care; it was just as fun, illuminating, and rewarding as the first one!</p><p>We kicked off this year’s datathon on October 25th with virtual attendance from 200+ medical students, residents, and graduate students from various medical and graduate schools across the United States. For a month, each team worked together using the MIMIC-IV dataset to identify high-impact problems related to value-based care data-driven solutions. Out of the 28 teams, seven finalists were selected to present at our live pitch event in front of five accomplished judges in the healthcare innovation space: <a href="https://www.linkedin.com/in/kathryn-a-teng-md-mba-facp-92b4405b/">Kathryn Teng, MD MBA FACP</a>; <a href="https://www.linkedin.com/in/amit-phull-09931667/">Amit Phull, MD</a>; <a href="https://www.linkedin.com/in/carolineberchuck/">Caroline Berchuck, MD MPH</a>; <a href="https://www.linkedin.com/in/reza-alavi-md-mba/">Reza Alavi, MD MHS MBA</a>; <a href="https://www.linkedin.com/in/sid-salvi/">Sid Salvi</a>.</p><p>After impressive pitches from each of the finalists, our judges selected the three winners of this year’s MD+ Datathon!</p><p>1st place</p><ul><li><strong>Project:</strong> Minimizing Chronic Kidney Disease (CKD) Underdiagnosis Using Machine Learning</li><li><strong>Team:</strong> Dany Alkurdi, Felipe Giuste, Lawrence Huang, Keyvon Rashidi, Sachin Shankar</li></ul><p>2nd place (tie)</p><ul><li><strong>Project: </strong>The Impact of Social Work Referrals on 30-Day Unplanned Hospital Readmissions of Alcohol-related Disorders</li><li><strong>Team: </strong>Amy Oh, Archita Goyal, Emily Leventhal, Lei Zhou</li></ul><p>2nd place (tie)</p><ul><li><strong>Project:</strong> Can We Curb Frequent ED Visits Due to Alcohol-Related Conditions?</li><li><strong>Team:</strong> Cailin Winston, Caleb Winston, Chloe Winston, Claris Winston, Cleah Winston</li></ul><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/0*Ceeuj6huH8oXHzpc" /></figure><p>We’d like to thank Hugging Face for providing computational resources for our datathon participants, Doximity and Conduce Health for their judge sponsorship, and Merck, for their sponsorship. Lastly, we want to spotlight MD+ Exec Members for working so hard the past month to put on this successful virtual datathon.</p><ul><li>Michael Yao — Perelman School of Medicine at the University of Pennsylvania</li><li>Eric Shan — Perelman School of Medicine at the University of Pennsylvania</li><li>Clara Sun — Case Western Reserve University School of Medicine</li><li>Steve Stephen — University of Rochester School of Medicine</li><li>Lathan Liou — Icahn School of Medicine at Mount Sinai</li></ul><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=17b677af3c33" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/recap-of-2023-md-datathon-17b677af3c33">Recap of 2023 MD+ Datathon</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Announcing the MD+ Podcast]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/mdplus/announcing-the-md-podcast-c29051abe81e?source=rss----ab0ea1775307---4"><img src="https://cdn-images-1.medium.com/max/1080/1*kqIDMONT2tzThv4CjsZPGg.png" width="1080"></a></p><p class="medium-feed-snippet">Hey MD+! We&#x2019;re excited to announce the launch of our MD+ Podcast! Our community has grown so much since starting in 2020. Within that time&#x2026;</p><p class="medium-feed-link"><a href="https://medium.com/mdplus/announcing-the-md-podcast-c29051abe81e?source=rss----ab0ea1775307---4">Continue reading on MDplus »</a></p></div>]]></description>
            <link>https://medium.com/mdplus/announcing-the-md-podcast-c29051abe81e?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/c29051abe81e</guid>
            <category><![CDATA[health-technology]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[podcast]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[innovation]]></category>
            <dc:creator><![CDATA[Lathan Liou]]></dc:creator>
            <pubDate>Thu, 29 Jun 2023 16:21:29 GMT</pubDate>
            <atom:updated>2023-06-29T16:21:29.919Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[Welcoming MD+ Exec 2023–2024]]></title>
            <link>https://medium.com/mdplus/welcoming-md-exec-2023-2024-7cd173a23a2c?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/7cd173a23a2c</guid>
            <category><![CDATA[medical-school]]></category>
            <category><![CDATA[medical-student]]></category>
            <category><![CDATA[healthcare]]></category>
            <dc:creator><![CDATA[Lathan Liou]]></dc:creator>
            <pubDate>Mon, 20 Mar 2023 19:49:43 GMT</pubDate>
            <atom:updated>2023-04-16T13:58:04.085Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*o9rLPSdpbq25HzYBSCua5w.png" /></figure><p>Hey MD+! As our community continues to expand and mature since our public inception in 2020 led by MD+ founder, Sherman, we are excited to welcome the third cohort of our <a href="https://mdplus.community/team">Executive Team</a> for this calendar year. <a href="https://www.linkedin.com/in/clara21sun?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAABVxJIUBeEhHn14vChhQma3GyFwf9aJaU0o&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BIa1dDereQKyn4VvmfmCf%2FA%3D%3D">Clara Sun</a>, our former VP of Community (MS3 at Case Western) has stepped up to Co-Chair our wonderful team with me this year. This post is meant to introduce the various friendly members of our team who can help point you where you want to go or serve as a sounding board for initiatives or peer career-planning.</p><h3>Returning Members</h3><p>We’re excited to welcome back:</p><ul><li><strong>co-VP of Growth</strong> (<a href="https://www.linkedin.com/in/kylielong1?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAB2lYF8BMSYq0NXuJ19JcdqJB_-nPZXnPk8&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BCNhNDl51S6e%2Br6f%2Br%2BqbyQ%3D%3D"><strong>Kylie</strong> Long</a>, MS1 at UMass)</li><li><strong>VP of Finance</strong> (<a href="https://www.linkedin.com/in/kylielong1?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAB2lYF8BMSYq0NXuJ19JcdqJB_-nPZXnPk8&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BCNhNDl51S6e%2Br6f%2Br%2BqbyQ%3D%3D"><strong>Tsikata</strong> Apenyo</a>, MD/MBA at Brown)</li><li><strong>Director of AI</strong> (<a href="https://www.linkedin.com/in/areebaabid?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAABNSdMQBT-oWdC8RjT3nGKZ06UmTc6Py3zY&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BH4ekX%2ByNT%2Fyx2oD3UW05uw%3D%3D"><strong>Areeba</strong> Abid</a>, MS2 at Emory)</li><li><strong>Director of Mentorship</strong> (<a href="https://www.linkedin.com/in/sarah-wenyon-590b14173?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAClHIzwBnmEoVtpsEC-Wu1QuR4XTqaQp5uA&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BilkCS02bTzO0AJTIZ5j8SA%3D%3D"><strong>Sarah</strong> Wenyon</a>, MS2 at Sidney Kimmel)</li><li><strong>Director of Blockchain</strong> (<a href="https://www.linkedin.com/in/wulftange?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACJ2Kc4Bp3Xw1I-eB5uRXUIICkooEALNYFM&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BK4GUQIDxREKX4Nue0cMRew%3D%3D"><strong>Will</strong> Wulftange</a>, MD/PhD at Case Western)</li><li><strong>Director of Medical Devices</strong> (<a href="https://www.linkedin.com/in/odlandian?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAABoYlNYBtbjy5gMWv4s6BZ3E_aat1BhUM10&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BbqY6bMNKSwKsRhL3fNV%2BeA%3D%3D"><strong>Ian</strong> Odland</a>, MS2 at Mount Sinai)</li><li><strong>Directors of Consulting</strong> (<a href="https://www.linkedin.com/in/navin-balaji-a84576153?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACTs0YQB5SoHVg5vrwmL74ox4RP7yCZ3njk&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3Bt%2FjfMBZUR2iClXhb0wgtTg%3D%3D"><strong>Navin</strong> Balaji</a>, MS4 at UMiami and <a href="https://www.linkedin.com/in/prateek-sahni?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACMM3pgB7vZH9MaXhDfar_NKzCFsamkfw_0&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BhYUn34dFSf%2BBK0wH3t7EDQ%3D%3D"><strong>Prateek</strong> Sahni</a>, MS2 at Columbia)</li></ul><h3>New Members</h3><p>Please meet our:</p><ul><li><strong>VPs of</strong> <strong>External Relations</strong> (<a href="https://www.linkedin.com/in/steve-j-stephen?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACGATsABW_T0qwbwKSsoUe93K5B5PDGIDr8&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BxZRy4RxpQ4Ol4fLmqpaDZg%3D%3D"><strong>Steve</strong> Stephen</a>, MS1 at URochester and <a href="https://www.linkedin.com/in/steve-j-stephen?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACGATsABW_T0qwbwKSsoUe93K5B5PDGIDr8&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BxZRy4RxpQ4Ol4fLmqpaDZg%3D%3D"><strong>Vamsi</strong> Chodisetty</a>, MS1 at Case Western)</li><li><strong>VPs of Communit</strong>y (<a href="https://www.linkedin.com/in/davidkulp1?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACCMR2UBzGCRkAtq7PrbNSPIbsvraB9jlDk&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BeDJF2qSMSbCQKCIkqzJBAg%3D%3D"><strong>David</strong> Kulp</a>, MS1 at Emory and <a href="https://www.linkedin.com/in/zac-schulman-7b4470136?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACEsC3gB2FWghYIW_q82rgLnMDXjuQTiL_8&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BwrbcXgLERziSm6cVGWUbkQ%3D%3D"><strong>Zac</strong> Schulman</a>, MS1 at Case Western)</li><li><strong>co-VP of Growth</strong> (<a href="https://www.linkedin.com/in/heath-rutledge-jukes-11a02b187?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACv23OYByszLMs50xy_PiG46QZ3PDv45550&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3Bx6COWblbT9mqrl%2FVYP1VFw%3D%3D"><strong>Heath</strong> Rutledge-Jukes</a>, MS1 at WashU St. Louis)</li><li><strong>Directors of Data</strong> (<a href="https://www.linkedin.com/in/michael-s-yao?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACkrU8MBQvKBzjkd_IgEC1ZcOlPQzGMnql8&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BEFjMNKlOTcqHaqISZmVs0Q%3D%3D"><strong>Michael</strong> Yao</a>, MD/PhD at Penn and <a href="https://www.linkedin.com/in/eric-z-shan?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAB_eUYgBzIcteDbwqXxWROK-DUUfogJX2nM&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BPhcFLPPUQyu72hFlVUNU5A%3D%3D"><strong>Eric</strong> Shan</a>, MS1 at Penn)</li><li><strong>Directors of VC</strong> (<a href="https://www.linkedin.com/in/rumana-ru-rashid-a37bb6105?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAABqyPUsBYvCfsQZtglYZ90b8bHEuwxWdD1E&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BMcsZBbulSWq0PRRBSmHUFg%3D%3D"><strong>Ru</strong> Rashid</a>, MD/PhD at Pitt and <a href="https://www.linkedin.com/in/jonathanwakim?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAABxh7sUBzcV0SdVDmSBL8xAgmwHyDkItkQ4&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3Bj3CFI1mgT4COkabfT7YDlg%3D%3D"><strong>Jonathan</strong> Wakim</a>, MD/MBA at Penn)</li><li><strong>Director of Biotech</strong> (<a href="https://www.linkedin.com/in/apurva-kanneganti-443268200?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAADNLtnMB32sO0mnRFQtFTgv4wvLvGpBLwWY&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BiYqw6Q9RSaqEPZbt6jdYDA%3D%3D"><strong>Apurva</strong> Kanneganti</a>, MD/PhD at Harvard)</li><li><strong>co-Director of Medical Devices</strong> (<a href="https://www.linkedin.com/in/arman-zadeh?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAAB6aZVkBP3WbDpbQj1cxQ5aQ0l6GFtd5yTg&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BEckOX4KLTOKMBCP6YUy2gA%3D%3D"><strong>Arman</strong> Zadeh</a>, MS1 at Case Western)</li><li><strong>Director of Health Policy</strong> (<a href="https://www.linkedin.com/in/archita-goyal?miniProfileUrn=urn%3Ali%3Afs_miniProfile%3AACoAACq6y5MBF9BW0VCxEFhvWKQpVzIuVOaruJs&amp;lipi=urn%3Ali%3Apage%3Ad_flagship3_search_srp_all%3BpVKK8iPXS5261avomT6CGQ%3D%3D"><strong>Archie</strong> Goyal</a>, MD/MPH at Tufts)</li></ul><p>We’re really excited to continue programming for the community and brainstorm ways we can create even closer forms of relationship and network-building.</p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*6SvBxopJk1dTZ8JXBq6GNQ.png" /><figcaption>MD+ Exec Team 2023–24</figcaption></figure><p>~ Lathan Liou and Clara Sun on behalf of the MD Exec Team 2023–2024</p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=7cd173a23a2c" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/welcoming-md-exec-2023-2024-7cd173a23a2c">Welcoming MD+ Exec 2023–2024</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Stepping off the clinical track to work in digital health]]></title>
            <link>https://medium.com/mdplus/stepping-off-the-clinical-track-to-work-in-digital-health-3135dede61e6?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/3135dede61e6</guid>
            <category><![CDATA[career-development]]></category>
            <category><![CDATA[digital-health]]></category>
            <category><![CDATA[health-technology]]></category>
            <category><![CDATA[civictech]]></category>
            <category><![CDATA[medical-school]]></category>
            <dc:creator><![CDATA[Kaeli Yuen, MD]]></dc:creator>
            <pubDate>Tue, 03 Jan 2023 00:01:42 GMT</pubDate>
            <atom:updated>2025-10-16T00:10:49.651Z</atom:updated>
            <content:encoded><![CDATA[<p><em>Hi! I’m </em><a href="https://www.linkedin.com/in/kaeliyuen/"><em>Kaeli</em></a><em>, an MD making my way in the world with no residency. I’ve worked in startups (</em><a href="https://www.akidolabs.com/"><em>Akido Labs</em></a><em>, </em><a href="https://www.humandx.org/"><em>The Human Diagnosis Project</em></a><em>), in the federal government as a </em><a href="https://presidentialinnovationfellows.gov/"><em>White House Presidential Innovation Fellow</em></a><em>, and am now leading a clinical product team at </em><a href="https://www.accolade.com/"><em>Accolade</em></a><em>.*</em></p><p><em>*As of 2023</em></p><figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*aPmOs1qhHMinqqGy0vaWDA.jpeg" /><figcaption>At my white coat ceremony in 2014 and beginning my first post-medical school job as a White House Presidential Innovation Fellow in 2019.</figcaption></figure><p>The decision to forgo residency was both exciting and nerve-wracking, and something about which physicians or physicians in training are often interested. I’m asked — <strong>“When did you decide not to practice clinically?”, “Do you ever regret your decision?”</strong>, and “<strong>What does your day-to-day work entail?” </strong>For those who may find it helpful, here is my story:</p><p>As a Chinese-American born into a family of doctors, going into medicine was always on my radar but not a foregone conclusion. In college, I was drawn toward computer science courses and considered it as a major. Though, I was a bit intimidated by classmates at Stanford who seemed far ahead of me in the field. After waffling about it for a couple years, I chose Biology so I could complete the pre-med requirements and finish a major on time.</p><h3><strong>VA Palo Alto: Introduction to clinical informatics</strong></h3><p>My first job out of college was as a Clinical Research Associate at Veterans Affairs (VA) Palo Alto. I had decided to pursue medical school, but hadn’t yet taken the MCAT and wanted some time off of being a student. Luckily, I landed a job combining my interests in medicine and technology: working with a research group developing clinical decision support applications for the VA electronic health record.</p><p>What was originally a gap year(s) filler job turned into a completely pivotal role for me. There, I was introduced to clinical informatics / decision support and was awed by its power: for example, an application developed by our small team influenced tens of thousands of hypertension medication decisions during a pilot implementation. So cool! Not only did this type of work have great potential for impact at scale, but it also offered at least a partial solution to the problem of care gaps from reliance on clinicians manually keeping up with new evidence.</p><p>My team at VA Palo Alto was led by Dr. Mary K Goldstein, an esteemed researcher and geriatrician. She and many of her collaborators were MDs who no longer practiced, who instead leveraged their clinical knowledge for clinical informatics work full-time. These folks became my career role models, and I set my sights on clinical informatics as an end game.</p><h3><strong>Keck School of Medicine: “Silicon Beach”</strong></h3><p>My medical school, Keck USC, was an excellent place to dive deeper into health technology. At the time, they offered an innovative “Health, Technology, and Engineering (HTE)” program, which paired USC PhD engineering students with medical students to collaborate on health tech projects. This program had spawned Akido Labs, a <a href="https://www.ycombinator.com/">Y-Combinator</a>-backed startup co-founded by a Keck medical student.</p><p>With the help of HTE Director Dr. George Tolomiczenko, I connected with the Akido Labs team and began working with them part-time during my first year at Keck. Through this role, I was exposed to new areas of health technology, including interoperability, Meaningful Use, and the FHIR HL7 standard. I also got hands-on experience with non-clinical, non-academic aspects of operating a startup/business, including developing product value propositions, recruiting and managing teams, crafting sales pitches, cultivating thought leadership, and more. I started to see there was work to be done in digital health that didn’t require a high level of clinical expertise.</p><p>Toward the end of first year, a revolutionary thought struck me: there was no reason I HAD to do residency! Yes, it is the typical next step after medical school, but I was by no means bound to take it. Up to that point, I’d been struggling to get excited about any particular specialty, and was mostly looking forward to getting residency “over with” so I could get back to building digital health tools. As soon as the idea occurred to me, I felt a huge wave of excitement, relief, and anticipation for the future. It felt right.</p><h3><strong>Medical school hiatus</strong></h3><p>I started to go through medical school with a new outlook: instead of stressing about becoming a top residency applicant, I approached studying with curiosity and gratitude for the rare opportunity to learn about the human body. I soaked in my clinical rotations, knowing they’d likely be my last experiences in those settings.</p><p>Still, part of me was afraid my decision might be a mistake. Would I be valuable in digital health without more legitimate clinical experience? Would the work be as fulfilling as I’d imagined? Would I be able to pay off my student loans? To help answer these questions, I decided to take a hiatus after third year to gain work experience and confidence in my decision.</p><p>I spent winter break of third year researching digital health companies. The Human Diagnosis Project (Human Dx), another Y-Combinator-backed startup, stood out for its mission that inspired and excited me. I LinkedIn messaged a medical student interning there to learn how I could join the team. After offering my full-time services for free — I told them I’d arrange for a research year stipend from school — I was in! That June, I moved from LA to DC to join the Human Dx team.</p><h3>Startup life</h3><p>The next two years were the busiest, most growth-filled I’ve had to date. The workload and pace at Human Dx were more demanding than most parts of medical school had been. Plus, I was completing a Stanford Biomedical Informatics certificate program online and occasionally returning to LA for medical school elective rotations.</p><p>I had joined Human Dx to gain experience and confidence, and that I certainly did. I got crash courses in product management, people management, organizational strategy and planning, sales/partnerships, community growth strategies, analytics, clinical informatics research, medical terminologies, and more. I learned to build products, processes, and teams from the ground up.</p><p>After a year at the company I became a salaried employee, and during my second year was promoted. I loved the work, felt valued by the team, and felt confident I’d gained skills that could transfer elsewhere. I was ready to return to LA and finish fourth year without applying to residency.</p><h3><strong>Post-graduation</strong></h3><p>I job searched and interviewed during my last rotations of fourth year. I received multiple offers, and accepted one as a White House Presidential Innovation Fellow at the <a href="https://www.oit.va.gov/about/index.cfm?">VA’s Office of the Chief Technology Officer</a>. There, I got to work on building clinical decision support for the VA once again. This time, I was on the IT side rather than clinical, and worked from VA Central Office rather than a regional VA healthcare system. This provided easier avenues toward scale and impact. My background as an MD allowed me to function as a clinical ambassador in IT-land, which helped build trust with clinical stakeholders.</p><p>After completing the Fellowship, I sought out the new experience of working with a larger health technology company. Now, I lead a product team at Accolade, Inc. that specializes in delivering products to our frontline care teams. I love building tools that let our teams focus on care rather than documentation. I’m enjoying getting deeper into value-based care, learning about business operations in the private sector, and growing as a leader in product. I’m grateful for the path I’ve taken and where it’s led me, and am looking forward to what comes next!</p><p><strong>…</strong></p><p><em>My experiences with startups and clinical informatics research groups during medical school were key to my success outside of clinical medicine. I’m interested in finding ways to help other medical students with similar interests build their non-clinical skillsets and resumes as well.</em></p><p><strong><em>Have you or has someone you know found creative ways to get non-clinical industry experiences while in medical school? I’d love to hear about it! Please reach out to me at kwyuen@alumni.stanford.edu</em></strong><em>.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=3135dede61e6" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/stepping-off-the-clinical-track-to-work-in-digital-health-3135dede61e6">Stepping off the clinical track to work in digital health</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Year in Review: MD+ in 2022]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/mdplus/year-in-review-md-in-2022-372bebe9aee7?source=rss----ab0ea1775307---4"><img src="https://cdn-images-1.medium.com/max/2600/1*ePI5Oxl85_oTyu5PMENUOg.jpeg" width="3024"></a></p><p class="medium-feed-snippet">A recap of our growing physician-innovator community in 2022 and what we&#x2019;re looking forward to in 2023</p><p class="medium-feed-link"><a href="https://medium.com/mdplus/year-in-review-md-in-2022-372bebe9aee7?source=rss----ab0ea1775307---4">Continue reading on MDplus »</a></p></div>]]></description>
            <link>https://medium.com/mdplus/year-in-review-md-in-2022-372bebe9aee7?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/372bebe9aee7</guid>
            <category><![CDATA[medical-school]]></category>
            <category><![CDATA[medical]]></category>
            <category><![CDATA[innovation]]></category>
            <dc:creator><![CDATA[Lathan Liou]]></dc:creator>
            <pubDate>Fri, 23 Dec 2022 18:35:23 GMT</pubDate>
            <atom:updated>2022-12-23T18:35:22.975Z</atom:updated>
        </item>
        <item>
            <title><![CDATA[A Beginner’s Guide to Biotech Venture Capital]]></title>
            <link>https://medium.com/mdplus/a-beginners-guide-to-biotech-venture-capital-13b6a5da395e?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/13b6a5da395e</guid>
            <category><![CDATA[entrepreneurship]]></category>
            <category><![CDATA[venture-capital]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[biology]]></category>
            <category><![CDATA[biotechnology]]></category>
            <dc:creator><![CDATA[william wulftange]]></dc:creator>
            <pubDate>Sun, 26 Jun 2022 21:23:47 GMT</pubDate>
            <atom:updated>2022-10-28T19:35:30.817Z</atom:updated>
            <content:encoded><![CDATA[<figure><img alt="" src="https://cdn-images-1.medium.com/max/1024/1*GbmZvry_y-j2Uk2qMequ5g.jpeg" /></figure><p>Biotechnology startup companies are unique from other startup ventures in that they have a high burn rate of capital and a long development process, making them very risky for investors. Novel biotechnology often faces legal and political battles during development (stem cells, mRNA vaccines) heightening the challenges that face burgeoning companies. Despite these risks, Venture Capital (VC) is a very important source of funding for biotechnology startups as it not only acts as a cash line, but also provides critical expertise that allow early-stage biotechnology companies to move through development and regulatory issues. So how does VC discern between good or bad investments? In this perspective, we will explore the characteristics of biotechnology companies that are evaluated by prospective VC partnerships.</p><p>The first screen for a biotechnology company is whether it fits within the VC’s investment strategy. An investment strategy can be based on target industries, demographics, development stages, geography, capital requirements, or any other number of factors. These requirements allow VCs to draw down focus significantly on a large pool of proposals. These factors may be based simply upon public opinion rather than larger VC ethos. For example, funding companies that rely on genetic modification of plants is generally not well received by large portions of the general public, despite the merit of the science. Some VCs simply do not have the capital to fund drug development, which can cost upwards of $1 billion USD over the course of decades.</p><p>If a company fits a VC’s overall investment strategy, the VC will perform due diligence in order to gauge its fitness and likelihood of success. Due diligence is the process through which VCs evaluate a company’s current state of affairs as well its potential growth — this includes a company’s management, current assets, liabilities, and where it may fit within the market. The weight of each criterion is highly debated, but it is speculated that the technological processes are more important in a company’s earlier stages, while management and sales become more important during later stages (1). Many biotechnology companies will not have revenue let alone profitability, which inhibits many methods of valuation. Due to the multi-year timeline required for a biotech product to progress from early phase discovery into a market-ready product, VCs will look for any indication of a product becoming obsolete or failing before inking a term sheet. For example, while shotgun sequencing techniques allowed for the first sequencing of the human genome around 2001, these techniques were largely replaced with next-generation sequencing techniques like RNA-seq by the early 2010s, meaning companies had to adapt or perish. For VCs, a long development process equates to nebulous exit strategies, adding more uncertainty and risk into an investment decision. So in order to conduct proper due diligence on a biotech company, VCs must progress through a logical flow that accounts for development, regulation, profit potential, and a dynamic market.</p><p>Due diligence can be performed by specialists within the VC or outsourced by more generalized VCs to experts, like scientists in a given field, physicians, other VCs, or other founders. Even specialized VCs will look for external validation though, which can be in the form of a strategic partnership with a larger company as it indicates additional faith in the company. During the due diligence process, analysts will examine a variety of characteristics including, finances, the current market, technology, and the managerial team. While there is no formula for how to weight the importance of these company attributes, generally speaking, team and technology matter more for early-stage biotech companies while market and finances matter more for later stage companies.</p><h3><em>Finances</em></h3><p>This characteristic of a company is the potential upside of a commercial product. The SARS-CoV-2 vaccines had tremendous upside as every human (and likely some primates) on the planet was a potential customer. Indeed, Moderna reported a total revenue of $18.5 bn for 2021, but it would be prudent to remember that when Moderna was receiving VC investments more than a decade ago, they would have been laughed at to suggest such an upside. The ability of a VC to turn a profit and the ability to exit the investment — in other words, liquidate stock options through an acquisition by another company or selling to the public through an initial public offering (IPO) — are repeatedly shown to be the most important metric of due diligence (2). Other considerations regarding a startup’s finances are whether the VC will be required to invest further and how much they may be diluted by further investment rounds as a result of giving away additional equity in exchange for capital.</p><h3><em>Market</em></h3><p>The market is everything outside of the biotechnology company, such as market size. For example, diseases like cancer have a massive market (calculated as the total number of patients or the total amount spent on treatments), which is good because there is potential for a lot of financial upside, but also means that a company may have a harder time breaking into the space due to competition. Cancer immunotherapies represent a space that has dramatically impacted the overall cancer market, but is still relatively new and thus has a lot of growth potential. For example, Chimeric Antigen Receptor (CAR) cells are immune cells primed to specifically attack cancerous cells and have only recently been introduced as commercial products. Currently there are only three FDA-approved CAR cell therapies and treatment costs the patient upwards of $1 million USD. With 1,200 clinical trials worldwide, this cost is expected to fall, but the overall market is expected to grow as new iterations CAR therapies are developed and brought into the commercial space (3). Technologies like these are attractive to VCs as the market will grow rapidly and eat into large portions of the dated chemotherapy market.</p><h3><em>Technology</em></h3><p>Since biotechnology can be so complex, VCs must be certain that the technology can be protected (can you patent the human genome?), that it will be accepted by the market, and that there is a functioning prototype. Even if a startup has patented their product, that doesn’t mean it is safe from legal disputes from competitors simply trying to silence other products. A recent example is the legal battle waging over CRISPR technology between Jennifer Doudna, PhD at University of California, Berkeley and Feng Zhang, PhD at Massachusetts Institute of Technology. While Doudna pioneered the conception of CRISPR-Cas9 technology, Zhang first applied the technology in mammalian cells and so a fight rages over this multi-billion-dollar technology.</p><h3><em>Management</em></h3><p>The entrepreneurial team can be the deciding factor as to whether a VC invests or not. In the first phase of biotech creation, many companies spin out of university research labs. The second phase is when the technology starts to take the form of a product, which needs to be sold. Science and sales are two very different skillsets, so the creators of the product are rarely the salesmen of the later stages of a biotech company. This is important to understand — scientific founders may start as C-suite executive members but rarely remain there as the company grows. While a company is growing, management has to be familiar with the science and understand it intimately so the founders can act as the managing team, but once the technology is developed, management doesn’t need such a deep understanding as much as they need the ability to sign contracts and sell the technology or product. Ultimately, the weighted value of the management team will be specific to the VC and their overall investment strategy.</p><p>These factors are the overarching criteria that VCs use when evaluating biotechnology companies. In this piece we did not go into some of the minute details VCs may inspect when deciding to invest (flow of physical lab space, quality of labs and equipment) as those are much more specific to individual VCs. Overall biotech companies are evaluated in a much different manner than other technology companies because of the unique path biotechnology must take for commercial success. Long development processes, high costs of maintaining a lab, and uncertain exit points increase the risk for investors. VCs can serve as an important catalyst in a fledgling biotech company, but the technology, market, and entrepreneurs must be there to assure that the company survives.</p><h3>References</h3><p><em>1. Bank of England. The financing of technology-based small firms. London: The Bank; 1996. 73 p. p.</em></p><p><em>2. MacMillan IC, Siegel R, Narasimha PS. Criteria used by venture capitalists to evaluate new venture proposals. Journal of Business venturing. 1985;1(1):119–28.</em></p><p><em>3. Polaris Market Research. CAR-T Cell Therapy Market Share, Size, Trends, Industry Analysis Report. 2022.</em></p><img src="https://medium.com/_/stat?event=post.clientViewed&referrerSource=full_rss&postId=13b6a5da395e" width="1" height="1" alt=""><hr><p><a href="https://medium.com/mdplus/a-beginners-guide-to-biotech-venture-capital-13b6a5da395e">A Beginner’s Guide to Biotech Venture Capital</a> was originally published in <a href="https://medium.com/mdplus">MDplus</a> on Medium, where people are continuing the conversation by highlighting and responding to this story.</p>]]></content:encoded>
        </item>
        <item>
            <title><![CDATA[Some Medical Student-Innovator Cognitive Distortions]]></title>
            <description><![CDATA[<div class="medium-feed-item"><p class="medium-feed-image"><a href="https://medium.com/mdplus/some-medical-student-innovator-cognitive-distortions-bc4bd9b75ac2?source=rss----ab0ea1775307---4"><img src="https://cdn-images-1.medium.com/max/1200/1*Xq5GxE1MYYj_CunRrtF_iA.jpeg" width="1200"></a></p><p class="medium-feed-snippet">Hopefully reassuring notes that give you a boost</p><p class="medium-feed-link"><a href="https://medium.com/mdplus/some-medical-student-innovator-cognitive-distortions-bc4bd9b75ac2?source=rss----ab0ea1775307---4">Continue reading on MDplus »</a></p></div>]]></description>
            <link>https://medium.com/mdplus/some-medical-student-innovator-cognitive-distortions-bc4bd9b75ac2?source=rss----ab0ea1775307---4</link>
            <guid isPermaLink="false">https://medium.com/p/bc4bd9b75ac2</guid>
            <category><![CDATA[medical-school]]></category>
            <category><![CDATA[motivation]]></category>
            <category><![CDATA[healthcare]]></category>
            <category><![CDATA[medicine]]></category>
            <category><![CDATA[mental-health]]></category>
            <dc:creator><![CDATA[Lathan Liou]]></dc:creator>
            <pubDate>Tue, 10 May 2022 11:36:54 GMT</pubDate>
            <atom:updated>2022-05-10T14:49:57.989Z</atom:updated>
        </item>
    </channel>
</rss>